Colorectal cancer (CRC) is the third most common cancer and the fourth most frequent cause of cancer deaths worldwide ([Weitz *et al*, 2005](#bib74){ref-type="other"}). The main prognostic factors in CRC are lymph node involvement, size of the tumour and local diffusion of disease ([Hellman and Rosenberg, 2001](#bib26){ref-type="other"}; [Hermanek and Sobin, 1995](#bib27){ref-type="other"}). However, these prognostic factors do not fully predict individual clinical outcome especially among stage II and III patients. Therefore, to improve clinical care, biological prognostic markers must be identified, especially for localised tumours.

Angiogenesis consists in the formation of new blood vessels from the endothelium of the existing vasculature. When a new tumour reaches the size of 1--2 mm, its ulterior growth requires the induction of new blood vessels, which may lead to the development of metastases. Angiogenesis is dependent on the balance between many stimulatory and inhibitory factors. Proangiogenic factors, such as vascular endothelial growth factor (VEGF), bind to sites on endothelial cells that lead to their proliferation.

Concerning the relationship between angiogenesis and clinical outcome, CRC has been one of the most studied tumours after breast cancer ([Uzzan *et al*, 2004](#bib67){ref-type="other"}). Microvessel density (MVD), as a surrogate marker of tumoral angiogenesis, has been proposed to identify patients at high risk of recurrence. Microvessel density assessment is the most commonly used technique to quantify intratumoral angiogenesis in cancer. It was first developed by [Weidner *et al* (1991)](#bib73){ref-type="other"} in 1991 and used panendothelial immunohistochemical staining of blood microvessels, mainly with Factor VIII related antigen (F. VIII Ag or von Willebrand\'s factor), CD31 or CD34, rarely CD105. Some authors used Chalkley count or computerised image analysis systems, both aimed to minimise the subjectivity in the quantification of MVD ([Chalkley, 1943](#bib10){ref-type="other"}).

Several methods were employed for the assessment of VEGF expression in the tumours: most often immunohistochemistry, but also RT--PCR or Northern Blot. Circulating VEGF may be related to the tumour, but is also certainly produced by platelets, granulocytes, monocytes; in addition, its determination may be technically difficult ([Vermeulen *et al*, 2002](#bib69){ref-type="other"}). Therefore, we decided not to include the studies relating circulating VEGF to survival in our meta-analysis (MA).

Many observational retrospective studies have concluded that MVD is inversely related to survival in CRC, but other studies did not reach this conclusion ([Poon *et al*, 2003](#bib52){ref-type="other"}). To determine whether angiogenesis, assessed by its surrogate end point MVD, and by the expression of the main angiogenic factor VEGF, is prognostic factor in CRC, we undertook a systematic review of the literature with a meta-analysis. Meta-analyses of observational studies may provide a useful tool for understanding and quantifying sources of variability in results across studies ([Stroup *et al*, 2000](#bib60){ref-type="other"}).

The aim of our study was to test the hypothesis that initially assessed MVD or VEGF expression would predict overall survival (OS colon cancer-related death) and/or relapse-free survival (RFS, recurrence at any site) in the global population of operated colon cancer patients. By doing so, we tried to contribute to convert MVD and/or VEGF expression from candidate to accepted prognostic factors in CRC. Actually, we performed four major meta-analyses including studies dealing with either MVD or VEGF expression for both OS and RFS. We also tried to study the relationship between MVD or VEGF expression and survival across various stages of CRC. Finally, we were interested to determine which of the two markers might be considered as the best angiogenic prognostic factor in localised or metastatic disease.

MATERIALS AND METHODS
=====================

Publication selection
---------------------

We performed our meta-analysis according to a predefined written protocol. To be eligible, studies had to deal with colon or rectum cancer, whatever the stage at inclusion of patients in the individual studies, and to assess the relationship between MVD or VEGF expression on one side and RFS or OS on the other side. Studies (full articles) were identified by an electronic search using online PubMed, with two distinct sets of key words used simultaneously in each set, namely 'colorectal cancer, neovascularization, prognosis\' and 'colorectal cancer, VEGF expression, prognosis\'. Last query was updated on 7 October 2004. We did another electronic search with the same key words using online EMBASE, which was unable to retrieve additional pertinent references. Our initial selection of articles relied on careful reading of their abstracts. Abstracts were reviewed from ASCO proceedings of the annual meetings from 1998 to 2004, but no additional data were found. We also screened references from the relevant literature, including all of the identified studies, but also reviews and editorials ([Papamichael, 2001](#bib48){ref-type="other"}; [Poon *et al*, 2003](#bib52){ref-type="other"}). We wrote or e-mailed to the authors of 20 studies (see [Appendix A](#app1){ref-type="app"}) for additional information and, in 5 occasions obtained the data needed for the meta-analytic calculations ([Choi *et al*, 1998](#bib11){ref-type="other"}; [Ishikawa *et al*, 1999](#bib30){ref-type="other"}; [Harada *et al*, 2001](#bib24){ref-type="other"}; [Khorana *et al*, 2003](#bib34){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}). We tried carefully to avoid duplication of data, by examining for each publication the names of all authors and the different medical centres involved. We excluded studies when their recruitment came from two distinct retrospective cohorts with different survivals ([Banner *et al*, 1998](#bib4){ref-type="other"}; [Nanashima *et al*, 1998](#bib45){ref-type="other"}; [Barozzi *et al*, 2002](#bib5){ref-type="other"}; [Saad *et al*, 2004](#bib54){ref-type="other"}), because we deemed their results could be biased.

Methodological assessment
-------------------------

Information was carefully extracted from all full publications in duplicate by the two readers (Gaëtan Des Guetz and Bernard Uzzan), using a standardised data collection form, including the following items: complete reference of the publication, original publication or update of a former publication, mode of making up of the series of cases, median duration of follow-up, number of patients included in the study, mean or median age, sex, anticancer treatment(s) during follow-up, histological type (adenocarcinoma or mucinous), tumour size, stage of disease, grade (good, moderate or poor differentiation), nodal status, optical reading of the slides with or without Chalkley count or image analysis system, number of readers of the slides, blinded reading (reader of the slides unaware of clinical information), type(s) of immunohistochemical staining, number of hot spots examined, magnification used, area of the field read, cutoff value for MVD (median MVD, unless otherwise stated, for example optimal cu-off ([Takebayashi *et al*, 1996](#bib62){ref-type="other"}; [Galindo Gallego *et al*, 2000](#bib19){ref-type="other"}), semiquantitative intensity of the VEGF expression (0, +, ++ or +++), number of events in each category of MVD or VEGF, RFS or OS or both, and results of uni- and multivariate analyses. Chalkley count was used in two studies ([White *et al*, 2002](#bib75){ref-type="other"}; [Li *et al*, 2003](#bib38){ref-type="other"}). Disagreements were resolved by consensus between the two readers. In case of persistent disagreement, the final decision was made by our experts (Gérard Perret for clinical evaluation, and Michel Cucherat for methodological and statistical assessment of data). We did not set a predefined minimal number of patients for a study to be included in our meta-analysis, nor a minimal duration of median follow-up. We did not weigh each study by a quality score, because no such score has received general agreement for use in a meta-analysis, especially of observational studies, making more difficult the evaluation of its usefulness ([Altman, 2001](#bib2){ref-type="other"}). Studies were not blinded to our readers, but exclusions were always decided without knowledge of the global result of each study. When duplicate studies were retrieved, we included in our systematic review, the study involving the highest number of patients from which data could be extracted (usually the latest). This was done to avoid overlapping between cohorts. Studies were usually retrospective, but sometimes consisted in a cohort of consecutive patients. Although their methodological quality and the reliability of their conclusions were variable, their design was almost similar, a favourable condition for our meta-analysis.

Statistical methods
-------------------

In each study, the relationship between MVD or VEGF expression and survival was considered significant when the *P*-value for the statistical test comparing survival distributions between the groups with high and low MVD (usually with median MVD as cutoff) was inferior to 0.05 in univariate analysis (two-tailed test). A study was termed 'positive\' or conclusive when a high MVD predicted poorer survival and 'negative\' or inconclusive when a high MVD did not predict a poor survival. In a few studies, a high MVD even predicted better survival ([Lindmark *et al*, 1996](#bib40){ref-type="other"}; [Abdalla *et al*, 1999](#bib1){ref-type="other"}; [Prall *et al*, 2003](#bib53){ref-type="other"}). Whenever possible, the parameter MVD was considered as a binary outcome and dichotomised by using its observed median. For the quantitative aggregation of survival results, we measured the impact of MVD on survival by estimating the risk ratio (RR) between the high or low MVD groups. For each trial, this RR was estimated by a method depending on the data provided in the publication. The simplest method consisted in the direct collection of RR, hazard ratio, or odds ratio, and their 95% confidence interval (CI) from the original article ([Amaya *et al*, 1997](#bib3){ref-type="other"}; [Tanigawa *et al*, 1997](#bib64){ref-type="other"}; [Ishigami *et al*, 1998](#bib29){ref-type="other"}; [Vermeulen *et al*, 1999](#bib70){ref-type="other"}; [Maeda *et al*, 2000](#bib42){ref-type="other"}; [White *et al*, 2002](#bib75){ref-type="other"}; [Kaio *et al*, 2003b](#bib33){ref-type="other"}; [Zheng *et al*, 2003](#bib76){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}; [Liang *et al*, 2004](#bib39){ref-type="other"}; [Tamura *et al*, 2004](#bib63){ref-type="other"}). If not available, we looked at the total numbers of events and the numbers of patients at risk in each group to determine the RR estimate. When data were only available as graphical survival plots, the calculations were carried out only if the number of steps on the curves equalled the number of events given in the publication, assuming that the rate of censored patients was constant during the study follow-up ([Parmar *et al*, 1998](#bib49){ref-type="other"}). In two studies, MVD was expressed as a continuous variable with no possibility to convert the corresponding HRs to their dichotomous counterparts so that they could not be incorporated into our meta-analytic calculations ([Takebayashi *et al*, 1996](#bib62){ref-type="other"}; [Lackner *et al*, 2004](#bib36){ref-type="other"}).

The heterogeneity between studies being difficult to investigate reliably, we chose to incorporate the assumption that the effect on survival between studies was not identical but followed some unknown distribution. Thus, we calculated a pooled random RR estimate and its 95% CI by using a random-effect model (Der Simonian and Laird\'s method). This method is more conservative because the CI around the random RR pooled estimate is wider than the CI around the fixed RR pooled estimate. By convention, an observed RR **\>**1 implied a worse prognosis in the high MVD or VEGF expression group. The detrimental impact of angiogenesis on survival was deemed statistically significant whenever the lower of the 95% CI of the overall RR was **\>**1. Comparisons of proportions of studies with or without various characteristics were made by *χ*^2^ tests. The statistical calculations for our meta-analyses were performed with EasyMA.net, Internet distributed application (Department of Clinical Pharmacology, Cardiology Hospital, Lyons, France) ([Cucherat *et al*, 1997](#bib13){ref-type="other"}).

RESULTS
=======

Our electronic data search using online PubMed and EMBASE retrieved a total of 153 references (107 dealing with MVD and 46 dealing with VEGF expression; full list available on request) including duplicate references since some publications studied both markers. After exclusion of the references which were out of the scope of our meta-analysis, there remained 45 studies dealing with MVD (see [Appendix B](#app2){ref-type="app"}) and 27 dealing with VEGF expression (see [Appendix C](#app3){ref-type="app"}), representing a total of 56 independent studies. Some of these articles did not fulfil our inclusion criteria (mainly because they did not mention survival data), six for MVD ([Vermeulen *et al*, 1995](#bib71){ref-type="other"}; [Banner *et al*, 1998](#bib4){ref-type="other"}; [Nanashima *et al*, 1998](#bib45){ref-type="other"}; [Kondo *et al*, 2000](#bib35){ref-type="other"}; [Barozzi *et al*, 2002](#bib5){ref-type="other"}; [Saad *et al*, 2004](#bib54){ref-type="other"}) and five for VEGF ([Nanashima *et al*, 1998](#bib45){ref-type="other"}; [Kondo *et al*, 2000](#bib35){ref-type="other"}; [Seto *et al*, 2000](#bib56){ref-type="other"}; [Barozzi *et al*, 2002](#bib5){ref-type="other"}; [Saad *et al*, 2004](#bib54){ref-type="other"}). One study was written in Chinese language, with an English abstract and did not seem to mention survival data ([Liu *et al*, 1999](#bib41){ref-type="other"}). Some publications corresponded to duplicate studies of the same marker, six for MVD ([Amaya *et al*, 1997](#bib3){ref-type="other"}; [Abdalla *et al*, 1999](#bib1){ref-type="other"}; [Galindo-Gallego *et al*, 2000](#bib18){ref-type="other"}; [Furudoi *et al*, 2002](#bib17){ref-type="other"}; [Kaio *et al*, 2003b](#bib33){ref-type="other"}; [Onogawa *et al*, 2004](#bib47){ref-type="other"}) and four for VEGF expression ([Amaya *et al*, 1997](#bib3){ref-type="other"}; [Furudoi *et al*, 2002](#bib17){ref-type="other"}; [Kaio *et al*, 2003b](#bib33){ref-type="other"}; [Onogawa *et al*, 2004](#bib47){ref-type="other"}) ([Figure 1](#fig1){ref-type="fig"}).

Almost all studies (*n*=40) used Dukes staging or derived classification (Astler-Coller). Two studies used only TNM staging ([Tanigawa *et al*, 1997](#bib64){ref-type="other"}; [Fox *et al*, 1998](#bib15){ref-type="other"}). Several studies used both classifications (see [Appendix D](#app4){ref-type="app"}). To better describe the patients included in our meta-analysis, we used Dukes staging whenever possible. For one study ([Ishikawa *et al*, 1999](#bib30){ref-type="other"}), in the absence of lymph node involvement or metastasis, we could convert stage T~1--3~N~0~M~0~ into stage A or B.

The main features of the eligible studies for MVD are summarized in [Table 1](#tbl1){ref-type="table"}. Thirty-two independent studies representing 3496 patients with mean age of 64.7 years (1740 male patients, 1400 female patients) included 1449 colon and 673 rectum cancers. These studies included 286 stage A, 1315 stage B, 1085 stage C and 388 stage D. There were only eight series of consecutive patients ([Lindmark *et al*, 1996](#bib40){ref-type="other"}; [Ishikawa *et al*, 1999](#bib30){ref-type="other"}; [Vermeulen *et al*, 1999](#bib70){ref-type="other"}; [Pietra *et al*, 2000](#bib51){ref-type="other"}; [Prall *et al*, 2003](#bib53){ref-type="other"}; [Shan *et al*, 2003](#bib57){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}; [Liang *et al*, 2004](#bib39){ref-type="other"}) and one prospective study ([Nanni *et al*, 2002](#bib46){ref-type="other"}), compared to 23 retrospective studies.

Finally, statistical calculations could be performed in 22 studies for MVD including nine studies (*n*=957) for RFS ([Engel *et al*, 1996](#bib14){ref-type="other"}; [Takahashi *et al*, 1997](#bib61){ref-type="other"}; [Choi *et al*, 1998](#bib11){ref-type="other"}; [Ishikawa *et al*, 1999](#bib30){ref-type="other"}; [Galindo Gallego *et al*, 2000](#bib19){ref-type="other"}; [Nanni *et al*, 2002](#bib46){ref-type="other"}; [Shan *et al*, 2003](#bib57){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}; [Liang *et al*, 2004](#bib39){ref-type="other"}) and 18 for OS (*n*=2383) (see [Appendix E](#app5){ref-type="app"}). High MVD significantly predicted poor RFS (RR=2.32; 95% CI: 1.39--3.90; *P*\<0.001) and poor OS (RR=1.44; 95% CI: 1.08--1.92; *P*=0.01).

Meta-analysis was also performed to relate VEGF expression and survival across all exploitable studies. The main features of eligible studies for VEGF are summarized in [Table 2](#tbl2){ref-type="table"}. Eighteen independent studies with 2050 patients with mean age 63.3 years (1041 male patients, 750 female patients) included 1104 colon cancers and 202 rectum cancers. These studies included 130 stage A, 472 stage B, 626 stage C and 149 stage D. Statistical calculations were performed for VEGF in 17 studies, including nine studies (*n*=1064) ([Amaya *et al*, 1997](#bib3){ref-type="other"}; [Takahashi *et al*, 1997](#bib61){ref-type="other"}; [Cascinu *et al*, 2000](#bib9){ref-type="other"}; [Maeda *et al*, 2000](#bib42){ref-type="other"}; [Cascinu *et al*, 2001](#bib8){ref-type="other"}; [Cascinu *et al*, 2002](#bib7){ref-type="other"}; [Nanni *et al*, 2002](#bib46){ref-type="other"}; [White *et al*, 2002](#bib75){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}) for RFS and 10 for OS (*n*=1301) ([Ishigami *et al*, 1998](#bib29){ref-type="other"}; [Tokunaga *et al*, 1998](#bib65){ref-type="other"}; [Lee *et al*, 2000](#bib37){ref-type="other"}; [Harada *et al*, 2001](#bib24){ref-type="other"}; [Nanni *et al*, 2002](#bib46){ref-type="other"}; [White *et al*, 2002](#bib75){ref-type="other"}; [Kaio *et al*, 2003b](#bib33){ref-type="other"}; [Khorana *et al*, 2003](#bib34){ref-type="other"}; [Zheng *et al*, 2003](#bib76){ref-type="other"}; [Tamura *et al*, 2004](#bib63){ref-type="other"}). High VEGF significantly predicted poor RFS (RR=2.84; 95% CI: 1.95--4.16; *P*\<0.001) and poor OS (RR=1.65; 95% CI: 1.27--2.14; *P*\<0.001). All four major meta-analyses gave statistically significant results, favouring a link between high MVD and VEGF expression and poor survival (see [Figure 2](#fig2){ref-type="fig"}).

We have shown previously in our meta-analysis relating MVD to survival in breast cancer that CD 31 and CD 34 were the best markers to predict survival compared with factor VIII ([Uzzan *et al*, 2004](#bib67){ref-type="other"}). Our present work confirms these findings for CRC. Actually a specific meta-analysis performed by using CD 31/CD34 in CRC gave higher RRs than the global meta-analysis (data not shown).

To determine whether MVD and/or VEGF expression are prognostic factors more suited to limited (stage A/B) or advanced disease (stage C/D), we divided the studies into those including a majority of limited forms, those including a majority of advanced forms and those where limited and advanced forms were balanced (mixed studies) which we omitted for being too few and ill-defined. For RFS and MVD, the RR for the studies with advanced forms (*n*=3) was higher than the RR for the studies with limited forms (*n*=7) (3.23 *vs* 2.49, these two^\*\*^ RRs being significantly different from 1 but not different from each other). These results are in favour of a prognostic role of MVD either in local or in advanced disease. For VEGF and RFS studies with localised disease (*n*=4), we found a RR of 4.05 (*P*\<0.001) compared with a RR of 3.41 (*P*\<0.001) for the studies with advanced disease (*n*=2). For MVD and VEGF expression and for OS, the RRs of the studies with limited and advanced disease were also significantly \>1, but less significant than for RFS.

Finally, we compared the ability of both angiogenic markers to predict survival by calculating the ratio of their RRs; for RFS, this ratio RR VEGF/RR MVD was found to be 1.22 (95% CI: 0.50--2.98), not significantly different from 1. However, the 95% CI width was smaller for VEGF than for MVD. The results were similar for OS.

DISCUSSION
==========

Our overview and meta-analysis of all published studies from which statistical data could be obtained or calculated showed that high MVD and VEGF expression, markers of angiogenesis, did indeed predict poor survival in patients with CRC.

However, our conclusions should be tempered for several reasons. First, the overall link we elicited between MVD and survival, although statistically significant, was rather weak, with a global RR of 1.44 for OS and 2.32 for RFS. However, for VEGF expression, these links were stronger (1.65 for OS; 2.84 for RFS). Empirically, RRs \>2 are considered strongly predictive ([Hayes *et al*, 2001](#bib25){ref-type="other"}). Both markers appeared more predictive for RFS than for OS, not surprisingly since OS is a more stringent parameter than RFS, harder to be influenced by treatments. We performed the meta-analyses including selectively the studies involving consecutive patients, supposed to be of better methodological quality, and found, rather unexpectedly, that the relation between survival and markers of angiogenesis was not improved for RFS, and even deteriorated for OS.

Our meta-analysis has several limitations. First, the level of evidence provided by MA of retrospective observational studies is lower than that of randomised controlled trials. Also, it relied on publications and not on individual data. But a meta-analysis on individual data would require the implication of many pathologists and a time-consuming processing of materials because of the large number of patients included in the studies and especially of their rather poor quality. There were several potential sources of heterogeneity between studies, but the Der Simonian and Laird method we used (random effect model) took them into account.

Studies may have differed in the baseline characteristics of patients included (age, tumour size, and stage), the adjuvant treatment they might have received for their cancer, the number of patients, the duration of follow-up. We attempted to minimise publication bias by making our literature search as complete as possible, using two databases (PubMed and EMBASE), reviewing ASCO meetings proceedings from 1998 to 2004 and crosschecking references. The discrepancies in the conclusions of various published studies could have encouraged researchers to publish their data whatever their results, thus limiting such publication bias. All publications but one ([Liu *et al*, 1999](#bib41){ref-type="other"}) were written in English language. The immunohistochemical marker used to assess MVD, or the method of microvessel count itself were sources of variability and represented potential selection biases. [Weidner *et al* (1991)](#bib73){ref-type="other"} used an antibody against factor VIII-related antigen, staining mainly mature vessels and cross-reacting with lymphatic endothelium. This marker remained the most used in the studies we reviewed. Several recent studies used antibodies directed against CD31 or CD34, best prognostic markers in CRC.

Many variations to the method of MVD assessment exist, although most studies used a technique similar to that of [Weidner *et al* (1991)](#bib73){ref-type="other"}. The size of the area examined varied between studies. Some authors considered the mean or the highest value among three or more determinations of MVD at different fields of the same hot spot ([Saclarides *et al*, 1994](#bib55){ref-type="other"}; [Lindmark *et al*, 1996](#bib40){ref-type="other"}; [Tanigawa *et al*, 1997](#bib64){ref-type="other"}; [van Triest *et al*, 2000](#bib68){ref-type="other"}). Some measured MVD as the mean or highest value at several hot spots ([Sokmen *et al*, 2001](#bib58){ref-type="other"}; [Shan *et al*, 2003](#bib57){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}; [Lackner *et al*, 2004](#bib36){ref-type="other"}). The choice of the cutoff value for MVD varied among studies, many used median MVD. In future studies, the assessment of these angiogenic prognostic factors should be better standardised, especially for patients for whom adjuvant therapy is recommended ([Vermeulen *et al*, 2002](#bib69){ref-type="other"}).

Prognostic biomarkers may be useful for identifying high-risk patients, leading to an improvement in their clinical or therapeutic management ([Weitz *et al*, 2005](#bib74){ref-type="other"}). Whereas in stage III CRC patients, adjuvant chemotherapy has been consistently shown to increase OS, in stage II it provides a small benefit, still uncertain. Meta-analyses gave conflicting results, one concluding to a small beneficial effect of chemotherapy ([Mamounas *et al*, 1999](#bib43){ref-type="other"}) and the other to the absence of benefit ([Gill *et al*, 2004](#bib23){ref-type="other"}). No study analysed separately the prognostic role of angiogenic markers among colon or rectum cancers. Microvessel density or VEGF expression might be predictive factors of the response to anti-angiogenic drugs (bevacizumab), now in phase III or IV trials ([Hurwitz *et al*, 2004](#bib28){ref-type="other"}). In metastatic CRC, MVD and VEGF expression did not predict the favourable response to bevacizumab in one retrospective study derived from the pivotal efficacy trial ([Jubb *et al*, 2006](#bib31){ref-type="other"}). Conversely, VEGF predicted rectal tumour response to preoperative radiotherapy ([Zlobec *et al*, 2005](#bib77){ref-type="other"}). Therefore, pathological markers such as MVD or VEGF expression would be helpful for individualisation of patients who would benefit from anti-angiogenic therapy.

We found a trend to a relationship between tumour stage (limited, advanced) and the capacity of angiogenesis markers to predict survival. There are pathophysiological grounds for such a relationship, since angiogenesis is a very early phenomenon in colon carcinogenesis and it is also essential to metastasis ([Garcea *et al*, 2004](#bib21){ref-type="other"}; [Wali *et al*, 2005](#bib72){ref-type="other"}). However, our findings might also be artefactual, since the definition of the three categories of studies was imprecise and there were few studies. According to our results, VEGF seemed to be a rather better angiogenic predictor of survival than MVD, due to a narrower 95% CI although the ratio of their RRs was not significantly different from 1. These last results should be interpreted cautiously, since this double factor analysis would ideally be performed on individual patients data.

The following recommendations should be made to future authors: include a large series of consecutive patients from a single cohort, stratify by tumour stage, fully describe the clinical characteristics of the study population, use antibodies directed against either CD31 or CD34 for immunostaining, present the results both as comparison of survival curves and as multivariate regression analysis and provide a full description of survival events to allow calculations. Future studies should include more homogeneous populations and should be prospective.

To conclude, our meta-analysis, representing a quantified synthesis of all published studies, found a statistically significant inverse relationship between angiogenesis, assessed by MVD or VEGF expression, and survival, confirming that, like breast cancer, human invasive colorectal cancer is an angiogenesis-dependent malignancy.

Addendum
--------

Our PubMed query was ultimately updated to 14 February 142006. The relation between survival and MVD was assessed in only two additional articles, a positive study including 60 patients for RFS (Acikalin *et al* (2005) Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. *Dig Liver Dis* **37:** 162--169) and a study of borderline significance including 92 patients for OS (Yonenaga *et al* (2005) Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. *Oncology* **69:** 159--166). The relation between survival and VEGF expression was assessed in two other articles, one negative study including 109 stage II colon cancers assessed for OS (Ochs *et al* (2004) Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. *Clin Colorectal Cancer* **4:** 262--267) and one positive study including 69 patients assessed for RFS and OS (Ferroni *et al* (2005) Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. *Oncology* **69:** 145--153). After incorporation into our meta-analysis of these four additional studies, the global RRs were very similar to the old ones, which could be expected from the small numbers of patients added and consequently the large CIs surrounding the RRs of these new studies. For MVD, the new RRs were 2.43 (95% CI: 1.49--3.96) for RFS and 1.46 (95% CI: 1.10--1.92) for OS. For VEGF, the new RR was 2.92 (95% CI: 2.04--4.17) for RFS (the RR for OS did not change. Thus, the conclusions of our four meta-analyses are identical before and after incorporation of these four new studies.

List of references of the twenty studies for which information was requested from the authors ([Saclarides *et al*, 1994](#bib55){ref-type="other"}; [Bossi *et al*, 1995](#bib6){ref-type="other"}; [Frank *et al*, 1995](#bib16){ref-type="other"}; [Mooteri *et al*, 1996](#bib44){ref-type="other"}; [Takebayashi *et al*, 1996](#bib62){ref-type="other"}; [Amaya *et al*, 1997](#bib3){ref-type="other"}; [Choi *et al*, 1998](#bib11){ref-type="other"}; [Pavlopoulos *et al*, 1998](#bib50){ref-type="other"}; [Tokunaga *et al*, 1998](#bib65){ref-type="other"}; [Ishikawa *et al*, 1999](#bib30){ref-type="other"}; [Sternfeld *et al*, 1999](#bib59){ref-type="other"}; [Lee *et al*, 2000](#bib37){ref-type="other"}; [Pietra *et al*, 2000](#bib51){ref-type="other"}; [van Triest *et al*, 2000](#bib68){ref-type="other"}; [Harada *et al*, 2001](#bib24){ref-type="other"}; [Giatromanolaki *et al*, 2002](#bib22){ref-type="other"}; [White *et al*, 2002](#bib75){ref-type="other"}; [Khorana *et al*, 2003](#bib34){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}; [Lackner *et al*, 2004](#bib36){ref-type="other"}).

List of the 45 references dealing with microvessel density which were within the scope of our meta-analysis ([Saclarides *et al*, 1994](#bib55){ref-type="other"}; [Bossi *et al*, 1995](#bib6){ref-type="other"}; [Frank *et al*, 1995](#bib16){ref-type="other"}; [Vermeulen *et al*, 1995](#bib71){ref-type="other"}; [Engel *et al*, 1996](#bib14){ref-type="other"}; [Lindmark *et al*, 1996](#bib40){ref-type="other"}; [Mooteri *et al*, 1996](#bib44){ref-type="other"}; [Takebayashi *et al*, 1996](#bib62){ref-type="other"}; [Tomisaki *et al*, 1996](#bib66){ref-type="other"}; [Amaya *et al*, 1997](#bib3){ref-type="other"}; [Takahashi *et al*, 1997](#bib61){ref-type="other"}; [Tanigawa *et al*, 1997](#bib64){ref-type="other"}; [Banner *et al*, 1998](#bib4){ref-type="other"}; [Choi *et al*, 1998](#bib11){ref-type="other"}; [Fox *et al*, 1998](#bib15){ref-type="other"}; [Nanashima *et al*, 1998](#bib45){ref-type="other"}; [Pavlopoulos *et al*, 1998](#bib50){ref-type="other"}; [Abdalla *et al*, 1999](#bib1){ref-type="other"}; [Ishikawa *et al*, 1999](#bib30){ref-type="other"}; [Liu *et al*, 1999](#bib41){ref-type="other"}; [Sternfeld *et al*, 1999](#bib59){ref-type="other"}; [Vermeulen *et al*, 1999](#bib70){ref-type="other"}; [Galindo-Gallego *et al*, 2000](#bib18){ref-type="other"}; [Galindo Gallego *et al*, 2000](#bib19){ref-type="other"}; [Kondo *et al*, 2000](#bib35){ref-type="other"}; [Pietra *et al*, 2000](#bib51){ref-type="other"}; [van Triest *et al*, 2000](#bib68){ref-type="other"}; [Sokmen *et al*, 2001](#bib58){ref-type="other"}; [Barozzi *et al*, 2002](#bib5){ref-type="other"}; [Cianchi *et al*, 2002](#bib12){ref-type="other"}; [Furudoi *et al*, 2002](#bib17){ref-type="other"}; [Giatromanolaki *et al*, 2002](#bib22){ref-type="other"}; [Nanni *et al*, 2002](#bib46){ref-type="other"}; [White *et al*, 2002](#bib75){ref-type="other"}; [Kaio *et al*, 2003a](#bib32){ref-type="other"}, [2003b](#bib33){ref-type="other"}; [Li *et al*, 2003](#bib38){ref-type="other"}; [Prall *et al*, 2003](#bib53){ref-type="other"}; [Shan *et al*, 2003](#bib57){ref-type="other"}; [Zheng *et al*, 2003](#bib76){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}; [Lackner *et al*, 2004](#bib36){ref-type="other"}; [Liang *et al*, 2004](#bib39){ref-type="other"}; [Onogawa *et al*, 2004](#bib47){ref-type="other"}; [Saad *et al*, 2004](#bib54){ref-type="other"}).

List of the twenty-seven references dealing with VEGF expression which were within the scope of our meta-analysis ([Amaya *et al*, 1997](#bib3){ref-type="other"}; [Takahashi *et al*, 1997](#bib61){ref-type="other"}; [Ishigami *et al*, 1998](#bib29){ref-type="other"}; [Nanashima *et al*, 1998](#bib45){ref-type="other"}; [Tokunaga *et al*, 1998](#bib65){ref-type="other"}; [Liu *et al*, 1999](#bib41){ref-type="other"}; [Cascinu *et al*, 2000](#bib9){ref-type="other"}; [Kondo *et al*, 2000](#bib35){ref-type="other"}; [Lee *et al*, 2000](#bib37){ref-type="other"}; [Maeda *et al*, 2000](#bib42){ref-type="other"}; [Seto *et al*, 2000](#bib56){ref-type="other"}; [van Triest *et al*, 2000](#bib68){ref-type="other"}; [Cascinu *et al*, 2001](#bib8){ref-type="other"}; [Harada *et al*, 2001](#bib24){ref-type="other"}; [Barozzi *et al*, 2002](#bib5){ref-type="other"}; [Cascinu *et al*, 2002](#bib7){ref-type="other"}; [Furudoi *et al*, 2002](#bib17){ref-type="other"}; [Nanni *et al*, 2002](#bib46){ref-type="other"}; [White *et al*, 2002](#bib75){ref-type="other"}; [Kaio *et al*, 2003a](#bib32){ref-type="other"}, [2003b](#bib33){ref-type="other"}; [Khorana *et al*, 2003](#bib34){ref-type="other"}; [Zheng *et al*, 2003](#bib76){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}; [Onogawa *et al*, 2004](#bib47){ref-type="other"}; [Saad *et al*, 2004](#bib54){ref-type="other"}; [Tamura *et al*, 2004](#bib63){ref-type="other"}).

List of the twelve references using Dukes and TNM classification [Takebayashi *et al*, 1996](#bib62){ref-type="other"}; [Choi *et al*, 1998](#bib11){ref-type="other"}; [Tokunaga *et al*, 1998](#bib65){ref-type="other"}; [Vermeulen *et al*, 1999](#bib70){ref-type="other"}; [Lee *et al*, 2000](#bib37){ref-type="other"}; [Maeda *et al*, 2000](#bib42){ref-type="other"}; [Harada *et al*, 2001](#bib24){ref-type="other"}; [Sokmen *et al*, 2001](#bib58){ref-type="other"}; [Cianchi *et al*, 2002](#bib12){ref-type="other"}; [Khorana *et al*, 2003](#bib34){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}.

List of the eighteen references dealing with microvessel density and overall survival for which statistical calculation were performed ([Lindmark *et al*, 1996](#bib40){ref-type="other"}; [Takebayashi *et al*, 1996](#bib62){ref-type="other"}; [Tomisaki *et al*, 1996](#bib66){ref-type="other"}; [Tanigawa *et al*, 1997](#bib64){ref-type="other"}; [Choi *et al*, 1998](#bib11){ref-type="other"}; [Fox *et al*, 1998](#bib15){ref-type="other"}; [Sternfeld *et al*, 1999](#bib59){ref-type="other"}; [Vermeulen *et al*, 1999](#bib70){ref-type="other"}; [Galindo Gallego *et al*, 2000](#bib19){ref-type="other"}; [Sokmen *et al*, 2001](#bib58){ref-type="other"}; [Cianchi *et al*, 2002](#bib12){ref-type="other"}; [Nanni *et al*, 2002](#bib46){ref-type="other"}; [Kaio *et al*, 2003b](#bib33){ref-type="other"}; [Li *et al*, 2003](#bib38){ref-type="other"}; [Prall *et al*, 2003](#bib53){ref-type="other"}; [Shan *et al*, 2003](#bib57){ref-type="other"}; [Zheng *et al*, 2003](#bib76){ref-type="other"}; [Galizia *et al*, 2004](#bib20){ref-type="other"}).

![Flow chart of the meta-analysis.](94-6603176f1){#fig1}

![Results of the four meta-analyses (**A**--**D**). RRs estimated with DerSimonian and Laird\'s random model.](94-6603176f2){#fig2}

###### 

Main characteristics of the studies relating microvessel density to MVD survival

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author Year of issue (reference)**                                             **Study from PubMed**   **Study design**   ***N* (M/F)**   **Colon (*n*)**   **Rectum (*n*)**   **Blinded reading**   **Reader(s) (*n*)**  **Mode of reading**   **Antibody**   **Extension**   **RR estimate**     **Survival analysis**   **Results**
  ------------------------------------------------------------------------------------- ----------------------- ------------------ --------------- ----------------- ------------------ --------------------- --------------------- --------------------- -------------- --------------- ------------------- ----------------------- -------------
  [Galizia *et al* (2004)](#bib20){ref-type="other"}                                              Yes                   C            104 (73/31)          104                0                   Yes                    2           Optical               CD34           Limited         Given by authors    OS, RFS                 Negative

  [Lackner *et al* (2004)](#bib36){ref-type="other"}                                              Yes                   R            70 (39/31)           49                 21                   ?                     ?           Optical               FVIII\         Mixed           Missing             ?                       Positive
                                                                                                                                                                                                                                                          CD34                                                                       

  [Liang *et al* (2004)](#bib39){ref-type="other"}                                                No                    C            114 (60/54)          77                 37                  Yes                    1           Optical               CD34           Advanced        Reported in text    RFS                     Positive

  [Kaio *et al* (2003a](#bib32){ref-type="other"}, [2003b)](#bib33){ref-type="other"}             Yes                   R            152 (94/58)           ?                 ?                    ?                     ?           Optical               CD34           Mixed           Survival curves     OS                      Negative

  [Prall *et al* (2003)](#bib53){ref-type="other"}                                                Yes                   C            173 (87/86)           ?                 ?                    ?                     1           Optical               FVIII          Mixed           Survival curves     OS                      Inverse

  [Li *et al* (2003)](#bib38){ref-type="other"}                                                   Yes                   R            111 (65/46)          83                 28                   ?                     ?           Chalkley              CD105\         Mixed           Survival curves     OS                      Positive
                                                                                                                                                                                                                                                          CD34                                                                       

  [Shan *et al* (2003)](#bib57){ref-type="other"}                                                 Yes                   C            104 (55/49)          72                 32                  Yes                    2           Optical               FVIII          Limited         Data extrapolated   OS, RFS                 Negative

  [Zheng *et al* (2003)](#bib76){ref-type="other"}                                                Yes                   R            97 (58/39)            ?                 ?                    ?                     ?           Optical               CD34           Mixed           Reported in text    OS                      Positive

  [Cianchi *et al* (2002)](#bib12){ref-type="other"}                                              Yes                   R            84 (60/24)            0                 84                  Yes                    2           Optical               CD31           Limited         Data extrapolated   OS                      Negative

  [Nanni *et al* (2002)](#bib46){ref-type="other"}                                                No                    P           263 (137/126)         263                0                   Yes                    2           Optical               FVIII          Mixed           Data extrapolated   OS, RFS                 Negative

  [White *et al* (2002)](#bib75){ref-type="other"}                                                Yes                   R            84 (42/42)           62                 22                  Yes                    2           Chalkley              CD31\          Limited         Missing             OS, RFS                 Inverse
                                                                                                                                                                                                                                                          FVIII                                                                      

  [Sokmen *et al* (2001)](#bib58){ref-type="other"}                                               Yes                   R            29 (18/11)            0                 29                  Yes                    2           Automated             FVIII          Mixed           Survival curves     OS                      Positive

  [Galindo-Gallego *et al* (2000)](#bib18){ref-type="other"}                                      Yes                   R            126 (70/56)          87                 39                   ?                     ?           Optical               CD34           Limited         Survival curves     OS, RFS                 Negative

  [Pietra *et al* (2000)](#bib51){ref-type="other"}                                               Yes                   C            119 (62/57)          78                 41                  Yes                    2           Optical               CD31           Mixed           Missing             OS, RFS                 Negative

  [Van Triest *et al* (2000)](#bib68){ref-type="other"}                                           Yes                   R            32 (13/19)           26                 6                   Yes                    2           Optical               CD31           Mixed           Missing             Missing                 ND

  [Giatromanolaki *et al* (2002)](#bib22){ref-type="other"}                                       No                    R            106 (65/41)          77                 29                   ?                     ?           Optical               CD31           Mixed           Missing             OS                      Positive

  [Ishikawa *et al* (1999)](#bib30){ref-type="other"}                                             Yes                   C            57 (34/23)            0                 57                  Yes                    2           Optical               CD31           Limited         Survival curves     RFS                     Positive

  [Sternfeld *et al* (1999)](#bib59){ref-type="other"}                                            Yes                   R              146 (?)            70                 76                   ?                     1           Optical               CD31           Limited         Survival curves     OS                      Positive

  [Vermeulen *et al* (1999)](#bib70){ref-type="other"}                                            No                    C            145 (75/70)          109                36                   ?                     ?           Optical               CD31           Advanced        Reported in text    RFS                     Positive

  [Choi *et al* (1998)](#bib11){ref-type="other"}                                                 Yes                   R            127 (72/55)           ?                 ?                   Yes                    2           Optical               FVIII          Advanced        Survival curves     OS, RFS                 Positive

  [Fox *et al* (1998)](#bib15){ref-type="other"}                                                  Yes                   R            36 (14/22)           36                 0                    ?                     ?           Optical               FVIII          ND              Survival curves     OS                      Negative

  [Pavlopoulos *et al* (1998)](#bib50){ref-type="other"}                                          Yes                   R            106 (56/50)           ?                 ?                   Yes                    ?           Automated             FVIII          Limited         Missing             Missing                 Negative

  [Tanigawa *et al* (1997)](#bib64){ref-type="other"}                                             Yes                   R            133 (76/57)           ?                 ?                   Yes                    2           Optical               CD34           Advanced        Reported in text    OS                      Positive

  [Takahashi *et al* (1997)](#bib61){ref-type="other"}                                            No                    R            27 (12/15)           27                 0                   Yes                    1           Optical               FVIII          Limited         Survival curves     RFS                     Positive

  [Engel *et al* (1996)](#bib14){ref-type="other"}                                                No                    R            35 (21/14)            ?                 ?                   Yes                    2           Optical               CD31           Limited         Data extrapolated   RFS                     Positive

  [Lindmark *et al* (1996)](#bib40){ref-type="other"}                                             No                    C           212 (90/122)          124                88                  Yes                    1           Optical               FVIII          Limited         Data extrapolated   OS                      Inverse

  [Mooteri *et al* (1996)](#bib44){ref-type="other"}                                              Yes                   R              32 (?)              ?                 ?                   Yes                    ?           Optical               FVIII          Advanced        Missing             Missing                 Negative

  [Takebayashi *et al* (1996)](#bib62){ref-type="other"}                                          Yes                   R           166 (108/58)           ?                 ?                   Yes                    2           Optical               FVIII          Limited         Survival curves     OS                      Positive

  [Tomisaki *et al* (1996)](#bib66){ref-type="other"}                                             No                    R            175 (98/77)           ?                 ?                    ?                     1           Optical               FVIII          Advanced        Data extrapolated   OS                      Negative

  [Frank *et al* (1995)](#bib16){ref-type="other"}                                                Yes                   R            105 (53/52)          105                0                   Yes                    ?           Optical               FVIII          Limited         Missing             Missing                 Positive

  [Bossi *et al* (1995)](#bib6){ref-type="other"}                                                 Yes                   R              178 (?)             ?                 ?                    ?                     1           Optical               CD31           Mixed           Missing             Missing                 Negative

  [Saclarides *et al* (1994)](#bib55){ref-type="other"}                                           Yes                   R            48 (33/15)            0                 48                  Yes                    1           Optical               FVIII          Mixed           Missing             Missing                 ND
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

C corresponds to studies including consecutive patients, R to retrospective studies without inclusion of consecutive patients. Extension means a predominance of limited forms (A/B), of advanced forms (C/D) or a balance between limited and advanced forms among the same study (mixed). RR estimate was either reported in text, or provided by mail by authors, or extrapolated from the data provided by authors in text, or estimated from the survival curves. A positive result means that there was an inverse relationship between MVD and survival, an inverse result means that there was a direct relationship between MVD and survival, and a negative result that there is no relationship. 'Readers\' are readers of the histologic slides, 'blinded reading\' means that readers of the slides were unaware of the clinical outcome of patients, and '?\' corresponds to missing data.

###### 

Main characteristics of the studies relating VEGF expression to survival

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author Year of issue (reference)**                                             **Study from PubMed**   **Study design**   ***N* (M/F)**   **Colon (*n*)**   **Rectum (*n*)**   **Blinded reading**   **Reader(s) (*n*)**  **VEGF assessment**    **Extension**   **RR Estimate**     **Survival analysis**   **Results**
  ------------------------------------------------------------------------------------- ----------------------- ------------------ --------------- ----------------- ------------------ --------------------- --------------------- ---------------------- --------------- ------------------- ----------------------- -------------
  [Galizia *et al* (2004)](#bib20){ref-type="other"}                                              Yes                   C            104 (73/31)          104                0                   Yes                    2           VEGF                   Limited         Reported in text    OS, RFS                 Positive

  [Tamura *et al* (2004)](#bib63){ref-type="other"}                                               Yes                   R            49 (35/14)           26                 23                  Yes                    2           VEGF                   Advanced        Reported in text    OS                      Negative

  [Kaio *et al* (2003a](#bib32){ref-type="other"}, [2003b)](#bib33){ref-type="other"}             Yes                   R            152 (94/58)           ?                 ?                    ?                     ?           VEGF-C                 Mixed           Reported in text    OS                      Positive

  [Khorana *et al* (2003)](#bib34){ref-type="other"}                                              Yes                   C            131 (69/62)          131                0                   Yes                    1           VEGF                   Advanced        Given by authors    OS                      Negative

  [Zheng *et al* (2003)](#bib76){ref-type="other"}                                                Yes                   R            97 (58/39)            ?                 ?                    ?                     ?           VEGF                   Mixed           Reported in text    OS                      Negative

  [Cascinu *et al* (2002)](#bib7){ref-type="other"}                                               Yes                   C            79 (44/35)            0                 79                  Yes                    2           VEGF                   Advanced        Reported in text    RFS                     Positive

  [Nanni *et al* (2002)](#bib46){ref-type="other"}                                                Yes                   P           263 (137/126)         263                0                    ?                     2           VEGF                   Mixed           Data extrapolated   OS, RFS                 Negative

  [White *et al* (2002)](#bib75){ref-type="other"}                                                Yes                   R            84 (42/42)           62                 22                  Yes                    2           VEGF-D\                Limited         Reported in text    OS, RFS                 Positive
                                                                                                                                                                                                                                    VEGFR-3                                                                            

  [Cascinu *et al* (2001)](#bib8){ref-type="other"}                                               Yes                   C            150 (90/60)          150                0                   Yes                    2           VEGF                   Advanced        Data extrapolated   RFS                     Positive

  [Harada *et al* (2001)](#bib24){ref-type="other"}                                               Yes                   C              259 (?)             ?                 ?                   Yes                    2           VEGF                   Mixed           Survival curves     OS                      Positive

  [Cascinu *et al* (2000)](#bib9){ref-type="other"}                                               Yes                   C            121 (71/50)          121                0                   Yes                    2           VEGF                   Limited         Data extrapolated   RFS                     Positive

  [Lee *et al* (2000)](#bib37){ref-type="other"}                                                  Yes                   C            145 (80/65)          102                43                  Yes                    2           VEGF                   Limited         Survival curves     OS                      Negative

  [Maeda *et al* (2000)](#bib42){ref-type="other"}                                                Yes                   R            100 (70/30)           ?                 ?                   Yes                    2           VEGF                   Mixed           Reported in text    RFS                     Positive

  [Van Triest *et al* (2000)](#bib68){ref-type="other"}                                           Yes                   R            32 (13/19)           26                 6                   Yes                    2           VEGF                   Mixed           Missing             Missing                 ND

  [Ishigami *et al* (1998)](#bib29){ref-type="other"}                                             Yes                   R            60 (40/20)           31                 29                   ?                     ?           VEGF (Northern blot)   Advanced        Reported in text    OS                      Positive

  [Tokunaga *et al* (1998)](#bib65){ref-type="other"}                                             Yes                   R            61 (34/27)           61                 0                    ?                     2           VEGF isoform pattern   ?               Survival curves     OS                      Positive

  [Takahashi *et al* (1997)](#bib61){ref-type="other"}                                            Yes                   R            27 (12/15)           27                 0                   Yes             Image analyzer     VEGF                   Limited         Data extrapolated   RFS                     Positive

  [Amaya *et al* (1997)](#bib3){ref-type="other"}                                                 No                    R            136 (79/57)           ?                 ?                   Yes                    2           VEGF                   Advanced        Reported in text    RFS                     Positive
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

C represents studies including consecutive patients, R retrospective studies including non consecutive patients, and P prospective studies. Extension means a predominance of limited forms (A, B), of advanced forms (C, D) or a balance between the 2 forms (mixed). RR estimate was either reported in text, or provided by mail by authors, or extrapolated from the data provided by authors in text, or estimated from the survival curves. A positive result means an inverse relationship between VEGF expression and survival and a negative result means no relationship.

'Readers\' are readers of the histologic slides, 'blinded reading\' means that readers of the slides were unaware of the clinical outcome of patients, and '?\' corresponds to missing data.
